Although it is generally accepted that the therapeutic effects of ARBs on hypertension and cardiovascular diseases are achieved mainly by directly blocking AT1R in the target of cardiovascular tissues (Akazawa et al., 2013), AT1R is widely distributed in other cells or tissues, such as immune cells, brain cells, or skeletal muscle cells (Marino et al., 2008; Zhou et al., 2015; Haspula and Clark, 2018; Deminice et al., 2020). This evidence concerns the gene AGTR1 and cardiovascular disorder.